Breast Cancer Biomarkers: Utility in Clinical Practice

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current Breast Cancer Reports

• Publication date

  2013-10-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12609-013-0125-9PMID 24416469PMCID PMC3882751
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cited by this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015cited by this paper
• Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis.

  2013cited by this paper
• Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.

  2013cited by this paper
• Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection.

  2013cited by this paper
• Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01).

  2013cited by this paper
• Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.

  2013cited by this paper
• Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

  2013cited by this paper
• Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.

  2013cited by this paper
• Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer

  2013cited by this paper
• Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients

  2013cited by this paper
• Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

  2013cited by this paper
• The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

  2013cited by this paper
• Analysis of circulating tumor DNA to monitor metastatic breast cancer.

  2013influential reference
• Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

  2012cited by this paper
• Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood

  2012cited by this paper
• Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

  2012cited by this paper
• Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy.

  2012influential reference
• CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

  2012cited by this paper
• Free Circulating Tumor DNA as a Diagnostic Marker for Breast Cancer

  2012cited by this paper
• Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies

  2012cited by this paper
• The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

  2012cited by this paper
• Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.

  2012cited by this paper
• Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

  2012cited by this paper
• Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay

  2012cited by this paper
• Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.

  2012cited by this paper
• Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.

  2012influential reference
• Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

  2012cited by this paper
• Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay

  2012cited by this paper
• Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

  2012cited by this paper
• Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

  2012cited by this paper
• High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.

  2012cited by this paper
• Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

  2012cited by this paper
• Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the TEAM pathology study.

  2012cited by this paper
• Beyond counting tumor cells

  2012cited by this paper
• Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study.

  2012cited by this paper
• Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.

  2012cited by this paper
• Tumour seeding following percutaneous needle biopsy: the real story!

  2011cited by this paper
• Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

  2011cited by this paper
• The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.

  2011cited by this paper
• Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

  2011cited by this paper
• Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients

  2011cited by this paper
• Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

  2011cited by this paper
• Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

  2011cited by this paper
• TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

  2011cited by this paper
• Multifactorial approach to predicting resistance to anthracyclines.

  2011cited by this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2011cited by this paper
• Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer

  2011cited by this paper
• Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression

  2011cited by this paper
• Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice.

  2011cited by this paper
• Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.

  2011cited by this paper
• Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer.

  2011cited by this paper
• Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells

  2011cited by this paper
• PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer: Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al (The Univ of Texas MD Anderson Cancer Ctr, Houston; et al) Mol Cancer Ther 10:1093-1101, 2011§

  2011cited by this paper
• Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal

  2011cited by this paper
• Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

  2011influential reference
• Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients

  2011cited by this paper
• P2-12-17: Prospective Evaluation of the Conversion Rate of HER2, ER and PR between Primary Tumors and Corresponding Metastases. CONVERTHER/GEICAM 2009–03 Study.

  2011cited by this paper
• PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

  2011cited by this paper
• A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

  2011cited by this paper
• Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.

  2011cited by this paper
• Assessment of Topoisomerase II (cid:1) Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization

  2011cited by this paper
• Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer.

  2011cited by this paper
• Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146

  2011cited by this paper
• Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

  2011cited by this paper
• Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology

  2011cited by this paper
• High genomic grade index associated with poor prognosis for lymph node‐negative and estrogen receptor‐positive breast cancers and with good response to chemotherapy

  2011cited by this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

  2010cited by this paper
• The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

  2010cited by this paper
• HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial

  2010cited by this paper
• Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

  2010cited by this paper
• Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.

  2010cited by this paper
• Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer.

  2010cited by this paper
• Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

  2010cited by this paper
• Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.

  2010cited by this paper
• Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)

  2010cited by this paper
• Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.

  2010cited by this paper
• The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

  2010cited by this paper
• Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells

  2009cited by this paper
• Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

  2009cited by this paper
• Genomic grade index is associated with response to chemotherapy in patients with breast cancer.

  2009cited by this paper
• Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

  2009cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009influential reference
• Development of the 21-gene assay and its application in clinical practice and clinical trials.

  2008cited by this paper
• Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials

  2008cited by this paper
• Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? The 2007 St Gallen guidelines and/or Adjuvant! Online.

  2008cited by this paper
• Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

  2007cited by this paper
• American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.

  2007cited by this paper
• American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

  2007cited by this paper
• A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

  2006cited by this paper
• Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

  2006cited by this paper
• Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

  2006cited by this paper
• Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

  2006cited by this paper
• Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer

  2005cited by this paper
• Adjuvant trastuzumab for HER2-positive breast cancer.

  2005cited by this paper
• Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

  2004cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004influential reference

• Profiling of Protein Adducts of Estrogen Quinones in 5-Year Survivors of Breast Cancer Without Recurrence

  2022cites this paper
• A review of prognostic and predictive biomarkers in breast cancer

  2022cites this paper
• HER2 Expression in Circulating Tumour Cells Isolated from Metastatic Breast Cancer Patients Using a Size-Based Microfluidic Device

  2021cites this paper
• Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches

  2021cites this paper
• Selection of a new peptide homing SK‐BR‐3 breast cancer cells

  2020cites this paper
• Disease Biomarker Discovery

  2019cites this paper
• Identification of a gene signature for different stages of breast cancer development that could be used for early diagnosis and specific therapy

  2018cites this paper
• Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker.

  2018cites this paper
• The impact of neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio among patients with intrahepatic cholangiocarcinoma

  2018cites this paper
• Breast Cancer Recurrence Risk Assessment: Is Non-Invasive Monitoring an Option?

  2018cites this paper
• Design and optimization of a microfluidic chip for single cell analysis of circulating tumor cells

  2018cites this paper
• Immunohistochemical features of multifocal and multicentric lobular breast carcinoma.

  2017cites this paper
• Performance of prognostic scores and staging systems in predicting long‐term survival outcomes after surgery for intrahepatic cholangiocarcinoma

  2017cites this paper
• Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer

  2017cites this paper
• Circulating Bone‐related Markers and YKL‐40 Versus HER2 and TOPO2a in Bone Metastatic and Nonmetastatic Breast Cancer: Diagnostic Implications

  2017cites this paper
• Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

  2015cites this paper
• Targeted Therapies in Triple-Negative Breast Cancer: Failure and Future

  2015cites this paper